FusionPlex® Pan Solid Tumor v2

OVERVIEW

The FUSIONPlex® Pan Solid Tumor v2 panel is designed for RNA-based next-generation sequencing (NGS) using the patented Anchored Multiplex PCR (AMP™) technology.

AMP™ (Anchored Multiplex PCR) is a patented targeted enrichment platform for next-generation sequencing. It uses unidirectional gene-specific primers (GSPs) and molecular adapters containing unique molecular barcodes (MBCs), which are ligated to the genetic material before amplification.

This strategy enables efficient capture and amplification of DNA, RNA or cfDNA fragments, even in the presence of unknown mutations or highly fragmented sequences.

Anchored Multiplex PCR technology workflow

The anchored primer architecture supports a flexible design and reduces information loss during library preparation. Combined with Archer™ Analysis software, AMP™ enables systematic error correction, read deduplication and accurate quantification of the original molecules.

This facilitates the detection of single-nucleotide variants, indels, gene fusions and copy-number alterations with high sensitivity and specificity.

RECOMMENDED TUMOUR TYPES

Colorectal cancer Breast cancer Melanoma Thyroid cancer Gastric cancer Pancreatic cancer Central nervous system tumours Non-small cell lung cancer Sarcoma Other cancer types
Recommended tumour types for the FUSIONPlex Pan Solid Tumor v2 panel

PROTOCOL

Standard version

The panel is designed for use with Illumina® and Ion Torrent® sequencers. The workflow is efficient and structured around two rounds of multiplex PCR, with library preparation taking approximately 1.5 days.

It requires a minimum amount of RNA or total nucleic acid (TNA), typically between 10 and 250 ng, extracted from FFPE samples or other clinical sources.

HT version (high throughput)

The panel is optimised for high-throughput workflows and Illumina® sequencers. It enables the simultaneous preparation of multiple libraries in 96-well plates using a scalable and automatable protocol that retains the sensitivity and accuracy of the standard design.

An input amount of 10 to 200 ng of RNA or TNA per sample is recommended, making it suitable for laboratories with a high analytical workload.

FUSIONPlex Pan Solid Tumor v2 library preparation workflow

SOFTWARE

Analysis performed using Archer™ Analysis software. Identification of known and novel gene fusions without requiring prior knowledge of the fusion partner. Detection of relevant alternative transcripts and splice variants. Use of molecular barcodes for read deduplication and accurate quantification of the original molecules. Correction of systematic sequencing and amplification errors. Generation of clear and customisable reports to facilitate the interpretation of results.

SPECIFICATIONS

The FUSIONPlex® Pan Solid Tumor v2 panel provides broad coverage of clinically relevant genes associated with a wide range of solid tumours.

FUSIONPlex Pan Solid Tumor v2 panel specifications
RNA-based targeted NGS panel. Detection of known and novel gene fusions. Detection of relevant alternative transcripts and splice variants. Compatible with RNA or total nucleic acid extracted from FFPE samples and other clinical sources. Standard workflow compatible with Illumina® and Ion Torrent® sequencing platforms. High-throughput HT workflow optimised for Illumina® platforms. Library preparation in approximately 1.5 days. Molecular barcodes for deduplication and accurate molecule quantification.

COMPLETE GENE LIST

AKT1 · ALK · AR · ARAF · BRAF · BRCA1 · BRCA2 · CCND1 · CDK4 · CDK6 · CIC · EGFR · ERBB2 · ERG · ESR1 · EWSR1 · FGFR1 · FGFR2 · FGFR3 · FOXO1 · FUS · JAK2 · KIT · KRAS · MAML2 · MDM2 · MET · MSH2 · MYB · MYBL1 · NTRK1 · NTRK2 · NTRK3 · NRAS · NRG1 · PDGFRA · PDGFRB · PIK3CA · PPARG · PRKCA · PRKCB · RAF1 · RELA · RET · ROS1 · RSPO2 · RSPO3 · TERT · TFE3 · TFEB · TMPRSS2 · VGLL2

Complete gene content of the FUSIONPlex Pan Solid Tumor v2 panel

Area:

Fusions, Pan-Cancer, Solid tumor

Brand:

Documents:

Consult our experts

Google reCaptcha: Invalid site key.

Related products

SureSelect Cancer CGP Assay

Targeted-enrichment NGS pan-cancer panel for comprehensive genomic profiling (CGP) of solid tumours. Designed to detect somatic variants at DNA level (SNVs, indels, CNVs, translocations) and RNA level (gene fusions), as well as to assess complex immuno-oncology biomarkers such as tumour mutational burden (TMB), microsatellite instability (MSI) and homologous recombination deficiency (HRD). Detailed Description Operating principle…
Agilent
Next Generation Sequencing (NGS)

SeqOne HRD Solution con Agilent SureSelect CD HRR17 Panel

HRD analysis solution combining low-coverage whole-genome sequencing (shallow/low-pass WGS) and a targeted gene panel to detect genomic instability, BRCA1/2 alterations and other genes related to homologous recombination. It is designed for laboratories wishing to implement HRD testing in-house with an automated, efficient and clinically validated workflow. Detailed Description SeqOne’s HRD solution combines shallow WGS and…
Agilent
Next Generation Sequencing (NGS)

OncoSELECT®

Comprehensive targeted liquid biopsy assay designed to support decision-making in oncology through the analysis of 74 clinically relevant genes. The solution encompasses everything from library preparation reagents to bioinformatics analysis, clinical interpretation and the generation of detailed reports. 3.- Detailed Description Operating principle OncoSELECT® is an advanced liquid biopsy panel based on circulating cell-free DNA…
OncoDNA
Next Generation Sequencing (NGS)

MSK-ACCESS® powered with SOPHiA DDM™

In-house liquid biopsy solution based on hybrid-capture next-generation sequencing (NGS) technology for the ultrasensitive detection of somatic alterations in circulating cell-free DNA from plasma. Developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), it implements a robust matched tumor-normal sequencing approach (plasma cfDNA + white blood cell DNA) to filter germline variants and mutations…
SOPHIA Genetics
Next Generation Sequencing (NGS)